Eflucimibe. Pierre Fabre/Eli Lilly.
Eflucimibe is an acyl coenzyme A:cholesterol acyltransferase inhibitor under development by Pierre Fabre SA and Eli Lilly & Co for the potential treatment of hypercholesterolemia and atherosclerosis. Phase II clinical trials commenced during 2002.
Department of Core Clinical Pathology & Biochemistry, Royal Perth Hospital and School of Surgery and Pathology, University of Western Australia, Wellington Street, GPO Box X2213, Perth, Western Australia 6847, Australia. john.burnett@health.wa.gov.au
John R
JR
Burnett
D000813:Anilides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000818:Animals; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors*
D000813:Anilides; D000924:Anticholesteremic Agents; C418062:eflucimibe; D002785:Sterol O-Acyltransferase